Injectable Lipid-Lowering Therapies Across the Chronic Kidney Disease Spectrum: Evidence, Safety, and a Stage-Specific Clinical Framework
Chronic kidney disease (CKD) confers a high burden of atherosclerotic cardiovascular disease (ASCVD) and a characteristic, evolving dyslipidaemia that is incompletely addressed by conventional care. Statin-based therapy remains first-line in most non-dialysis CKD populations, yet many patients fail to reach lipid goals...